GLP-1类似物和受体激动剂对2型糖尿病合并肥胖及单纯肥胖患者体重影响的研究进展  

Advances in Research on Effects of GLP-1 Analogues and Receptor Agonists on Body Weight in Patients with Type 2 Diabetes Mellitus Complicated with Obesity and Patients with Simple Obesity

作　　者：姜露 厉平[1] JIANG Lu;LI Ping(Department of Endocrinology,Shengjing Hospital,China Medical University,Shenyang 110020,China)

机构地区：[1]中国医科大学附属盛京医院内分泌科

出　　处：《医学综述》2020年第2期341-345,共5页Medical Recapitulate

基　　金：国家自然科学基金(81600644)

摘　　要：作为抗高血糖药物,胰高血糖素样肽1(GLP-1)类似物和胰高血糖素样肽1受体(GLP-1R)激动剂已成为2型糖尿病(T2DM)合并肥胖患者降糖的同时可以减重治疗的新选择。从基础研究到临床研究,从减重机制到临床效果,医学界不断有新证据出现。目前认为,GLP-1类似物和GLP-1R激动剂主要通过对神经系统的直接作用、对胃肠道的直接作用以及对白色脂肪棕色化的影响来实现减重效果,国际上多项大型试验也证实其对体重减轻的影响;与此同时,国际上在GLP-1类似物和受体激动剂对非糖尿病的单纯性肥胖患者的减重效果和安全也做了积极探索。As an antihyperglycemic drug,glucagon-like peptide-1( GLP-1) analogue and glucagon-like peptide-1 receptor( GLP-1 R) Agonists have become new choices for type 2 diabetes( T2 DM) combined with obesity in patients for lowering both glucose and weight. From basic research to clinical research,from weight loss mechanism to clinical effects,tnew evidence have been emerging in the medical field. And it is currently believed that these drugs mainly achieve weight loss through direct effects on the nervous system,direct effects on the gastrointestinal tract,and browning of white fat. Many large international trials have also confirmed their effect on weight loss. At the same time,internationally,GLP-1 analogues and receptor agonists have also been actively explored for its weight loss effect and safety on non-diabetic patients with simple obesity.

关 键 词：2型糖尿病 肥胖 胰高血糖素样肽1类似物 胰高血糖素样肽1受体 

分 类 号：R452[医药卫生—治疗学] R587.1[医药卫生—临床医学]